Duration
18 months
Cost
Free to Patients
Phase
Phase III
Closes
Oct 2025
Evaluating luspatercept in lower-risk MDS patients with ring sideroblasts and transfusion dependence.
Only 23 spots remaining
Apply soon to secure your place.
Check your eligibility in under 2 minutes. No commitment required β a coordinator will guide you through next steps.
Check My Eligibility βFree to apply Β· No medical records needed to start
Trial Summary